doxycycline (doxy Search Results


chem impex doxycycline  (Chem Impex International)
95
Chem Impex International chem impex doxycycline
Chem Impex Doxycycline, supplied by Chem Impex International, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/chem impex doxycycline/product/Chem Impex International
Average 95 stars, based on 1 article reviews
chem impex doxycycline - by Bioz Stars, 2026-03
95/100 stars
  Buy from Supplier
dox  (Valiant Co Ltd)
95
Valiant Co Ltd dox
Dox, supplied by Valiant Co Ltd, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/dox/product/Valiant Co Ltd
Average 95 stars, based on 1 article reviews
dox - by Bioz Stars, 2026-03
95/100 stars
  Buy from Supplier
doxycycline  (European Directorate for the Quality of Medicines and HealthCare)
92
European Directorate for the Quality of Medicines and HealthCare doxycycline
Doxycycline, supplied by European Directorate for the Quality of Medicines and HealthCare, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/doxycycline/product/European Directorate for the Quality of Medicines and HealthCare
Average 92 stars, based on 1 article reviews
doxycycline - by Bioz Stars, 2026-03
92/100 stars
  Buy from Supplier
doxycycline (200 mg/kg doxy chow)  (Bio-Serv)
90
Bio-Serv doxycycline (200 mg/kg doxy chow)
Doxycycline (200 Mg/Kg Doxy Chow), supplied by Bio-Serv, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/doxycycline (200 mg/kg doxy chow)/product/Bio-Serv
Average 90 stars, based on 1 article reviews
doxycycline (200 mg/kg doxy chow) - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier
doxycycline doxy-lemmon  (Vibra Screw Inc)
90
Vibra Screw Inc doxycycline doxy-lemmon
Doxycycline Doxy Lemmon, supplied by Vibra Screw Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/doxycycline doxy-lemmon/product/Vibra Screw Inc
Average 90 stars, based on 1 article reviews
doxycycline doxy-lemmon - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier
doxycycline (doxy) in a concentration of 625 mg of doxy/kg  (ssniff Spezialdiaten)
90
ssniff Spezialdiaten doxycycline (doxy) in a concentration of 625 mg of doxy/kg
(A) ShTaz <t>doxycycline</t> breeding scheme. ( B ) Body weight of Taz -KD and WT at 10 and 50 wo, N (10 wo, WT) = 5, N (10 wo, Taz -KD) = 6, N (50 wo, WT) = 9, N (50 wo, Taz -KD) = 10. Paired analysis of Taz gene expression in heart ( C ) and pancreatic islet ( D ) tissue, N = 3. ( E ) Complete lipid class profile (logarithmic scaling) of pancreatic islets from 20 wo WT and Taz - KD, N = 4. ( F ) Significantly (p < 0.05) altered lipid species in Taz -KD pancreatic islets. Data represent mean ± SEM (indicated by error bars); N numbers indicate number of animals; statistical significance was determined by unpaired Student t test: *p < 0.05, **p < 0.01, ****p < 0.0001. Abbreviations: weeks of age (wo), Tafazzin -Knockdown ( Taz -KD), Wildtype (WT), area under curve (AUC), glucose tolerance test (GTT), lipid class abbreviations can be found in (Supplementary material: Abbreviation of lipids).
Doxycycline (Doxy) In A Concentration Of 625 Mg Of Doxy/Kg, supplied by ssniff Spezialdiaten, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/doxycycline (doxy) in a concentration of 625 mg of doxy/kg/product/ssniff Spezialdiaten
Average 90 stars, based on 1 article reviews
doxycycline (doxy) in a concentration of 625 mg of doxy/kg - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier
doxycycline (doxy  (Genero Pharmaceuticals)
90
Genero Pharmaceuticals doxycycline (doxy
Peak plasma concentration of Lopinavir/Ritonavir (LOPIRITO), Azithromycin (AZI), <t> Clarithromycin </t> (CLA), <t> Doxycycline (DOXY), </t> Hydroxychloroquine (HCQ), and Favipiravir (FAVI) after a single oral administration of the drug.
Doxycycline (Doxy, supplied by Genero Pharmaceuticals, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/doxycycline (doxy/product/Genero Pharmaceuticals
Average 90 stars, based on 1 article reviews
doxycycline (doxy - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier
doxycycline gel doxy  (Ivoclar Vivadent US)
90
Ivoclar Vivadent US doxycycline gel doxy
Peak plasma concentration of Lopinavir/Ritonavir (LOPIRITO), Azithromycin (AZI), <t> Clarithromycin </t> (CLA), <t> Doxycycline (DOXY), </t> Hydroxychloroquine (HCQ), and Favipiravir (FAVI) after a single oral administration of the drug.
Doxycycline Gel Doxy, supplied by Ivoclar Vivadent US, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/doxycycline gel doxy/product/Ivoclar Vivadent US
Average 90 stars, based on 1 article reviews
doxycycline gel doxy - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier
doxycycline (doxy)  (Aladdin Co Ltd)
90
Aladdin Co Ltd doxycycline (doxy)
Peak plasma concentration of Lopinavir/Ritonavir (LOPIRITO), Azithromycin (AZI), <t> Clarithromycin </t> (CLA), <t> Doxycycline (DOXY), </t> Hydroxychloroquine (HCQ), and Favipiravir (FAVI) after a single oral administration of the drug.
Doxycycline (Doxy), supplied by Aladdin Co Ltd, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/doxycycline (doxy)/product/Aladdin Co Ltd
Average 90 stars, based on 1 article reviews
doxycycline (doxy) - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier

Image Search Results


(A) ShTaz doxycycline breeding scheme. ( B ) Body weight of Taz -KD and WT at 10 and 50 wo, N (10 wo, WT) = 5, N (10 wo, Taz -KD) = 6, N (50 wo, WT) = 9, N (50 wo, Taz -KD) = 10. Paired analysis of Taz gene expression in heart ( C ) and pancreatic islet ( D ) tissue, N = 3. ( E ) Complete lipid class profile (logarithmic scaling) of pancreatic islets from 20 wo WT and Taz - KD, N = 4. ( F ) Significantly (p < 0.05) altered lipid species in Taz -KD pancreatic islets. Data represent mean ± SEM (indicated by error bars); N numbers indicate number of animals; statistical significance was determined by unpaired Student t test: *p < 0.05, **p < 0.01, ****p < 0.0001. Abbreviations: weeks of age (wo), Tafazzin -Knockdown ( Taz -KD), Wildtype (WT), area under curve (AUC), glucose tolerance test (GTT), lipid class abbreviations can be found in (Supplementary material: Abbreviation of lipids).

Journal: bioRxiv

Article Title: Pancreatic islets undergo functional and morphological adaptation during development of Barth Syndrome

doi: 10.1101/2024.06.28.601122

Figure Lengend Snippet: (A) ShTaz doxycycline breeding scheme. ( B ) Body weight of Taz -KD and WT at 10 and 50 wo, N (10 wo, WT) = 5, N (10 wo, Taz -KD) = 6, N (50 wo, WT) = 9, N (50 wo, Taz -KD) = 10. Paired analysis of Taz gene expression in heart ( C ) and pancreatic islet ( D ) tissue, N = 3. ( E ) Complete lipid class profile (logarithmic scaling) of pancreatic islets from 20 wo WT and Taz - KD, N = 4. ( F ) Significantly (p < 0.05) altered lipid species in Taz -KD pancreatic islets. Data represent mean ± SEM (indicated by error bars); N numbers indicate number of animals; statistical significance was determined by unpaired Student t test: *p < 0.05, **p < 0.01, ****p < 0.0001. Abbreviations: weeks of age (wo), Tafazzin -Knockdown ( Taz -KD), Wildtype (WT), area under curve (AUC), glucose tolerance test (GTT), lipid class abbreviations can be found in (Supplementary material: Abbreviation of lipids).

Article Snippet: Doxycycline (doxy) in a concentration of 625 mg of doxy/kg was added to the standard rodent chow (A153D70623, Ssniff, Germany) leading to induction of short hairpin RNA (shRNA)-mediated knockdown of Taz , as described previously ( ).

Techniques: Expressing, Knockdown

( A ) Generation of a new mouse (shTaz x Mito-roGFP2-Orp1) model that expresses an shRNA against Taz and the mitochondrial H 2 O 2 sensor roGFP2-Orp1. The mice are lifelong feed with doxy. Figure created with Biorender.com. ( B ) Schematic protocol of redox histology to measure in vivo redox state. Before pancreas isolation, shTaz x Mito-roGFP2-Orp1 mice are perfused with NEM via the cardiovascular system. Isolated pancreas is fixed in PFA und cryocuts are staining against insulin to localize the pancreatic islets. Imaged intensity ratio (excitation: 405/488 nm and emission: 500 – 530 nm) of the mito-roGFP2-Orp1 sensor in pancreatic islets reflects the in vivo redox status. ( C ) Representative ratiometric image (ImageJ Lookup table: “Fire”) of mito-roGFP2-Orp1/WT (left) and mito-roGFP2-Orp1/ Taz -KD (right) pancreatic islets at 20 (top) or 50 wo (bottom). Scale bar: 100 µm. ( D ) Normalized percentage change in ratio of the redox state of the mito-roGFP2-Orp1 sensor in pancreatic islets of 20 (left) and 50 (right) wo mito-roGFP2-Orp1/WT and mito-roGFP2-Orp1/ Taz -KD mice. DTT was used as a reductive control (blue). N (WT, 20 wo) = 7, N ( Taz -KD, 20 wo) = 7, N (DTT, 20 wo) = 8, N (WT, 50 wo) = 4, N ( Taz -KD, 50 wo) = 4, N (DTT, 50 wo) = 6. ( E ) Real-time H 2 O 2 imaging of ex vivo 20 wo mito-roGFP2-Orp1/WT and mito-roGFP2-Orp1/ Taz -KD pancreatic islets. Pancreatic islets were incubated with RPMI 1640 at 5% CO 2 and 37 °C, in presence or absence of 1 µM Auranofin and 100 µM exogenously added H 2 O 2 , N = 5. A schematic figure illustrates the CD7 redox measurement with isolated islets, created with Biorender.com. ( F ) Representative western blot and quantification of Prx3 (left), Cat (middle) and GPX4 (right) normalized to β-actin in pancreatic islets of 20 wo Taz -KD mice, N (Prx3) = 4, N (Cat) = 3, N (GPX4) = 4. Data represent mean ± SEM (indicated by error bars); N and n numbers indicate number of animals and experiments, respectively; statistical significance was determined by unpaired Student t test: *p < 0.05, **p < 0.01. Abbreviations: Mitochondria-redox-sensitive- GFP2-Orp1 (Mito-roGFP2-Orp1), doxycycline (doxy), weeks of age (wo), Tafazzin -Knockdown ( Taz -KD), Wildtype (WT), Dithiothreitol (DTT), glucose (Glu, G), catalase (Cat), peroxiredoxin 3 (Prx3), glutathionperoxidase 4 (GPX4), area under the curve (AUC).

Journal: bioRxiv

Article Title: Pancreatic islets undergo functional and morphological adaptation during development of Barth Syndrome

doi: 10.1101/2024.06.28.601122

Figure Lengend Snippet: ( A ) Generation of a new mouse (shTaz x Mito-roGFP2-Orp1) model that expresses an shRNA against Taz and the mitochondrial H 2 O 2 sensor roGFP2-Orp1. The mice are lifelong feed with doxy. Figure created with Biorender.com. ( B ) Schematic protocol of redox histology to measure in vivo redox state. Before pancreas isolation, shTaz x Mito-roGFP2-Orp1 mice are perfused with NEM via the cardiovascular system. Isolated pancreas is fixed in PFA und cryocuts are staining against insulin to localize the pancreatic islets. Imaged intensity ratio (excitation: 405/488 nm and emission: 500 – 530 nm) of the mito-roGFP2-Orp1 sensor in pancreatic islets reflects the in vivo redox status. ( C ) Representative ratiometric image (ImageJ Lookup table: “Fire”) of mito-roGFP2-Orp1/WT (left) and mito-roGFP2-Orp1/ Taz -KD (right) pancreatic islets at 20 (top) or 50 wo (bottom). Scale bar: 100 µm. ( D ) Normalized percentage change in ratio of the redox state of the mito-roGFP2-Orp1 sensor in pancreatic islets of 20 (left) and 50 (right) wo mito-roGFP2-Orp1/WT and mito-roGFP2-Orp1/ Taz -KD mice. DTT was used as a reductive control (blue). N (WT, 20 wo) = 7, N ( Taz -KD, 20 wo) = 7, N (DTT, 20 wo) = 8, N (WT, 50 wo) = 4, N ( Taz -KD, 50 wo) = 4, N (DTT, 50 wo) = 6. ( E ) Real-time H 2 O 2 imaging of ex vivo 20 wo mito-roGFP2-Orp1/WT and mito-roGFP2-Orp1/ Taz -KD pancreatic islets. Pancreatic islets were incubated with RPMI 1640 at 5% CO 2 and 37 °C, in presence or absence of 1 µM Auranofin and 100 µM exogenously added H 2 O 2 , N = 5. A schematic figure illustrates the CD7 redox measurement with isolated islets, created with Biorender.com. ( F ) Representative western blot and quantification of Prx3 (left), Cat (middle) and GPX4 (right) normalized to β-actin in pancreatic islets of 20 wo Taz -KD mice, N (Prx3) = 4, N (Cat) = 3, N (GPX4) = 4. Data represent mean ± SEM (indicated by error bars); N and n numbers indicate number of animals and experiments, respectively; statistical significance was determined by unpaired Student t test: *p < 0.05, **p < 0.01. Abbreviations: Mitochondria-redox-sensitive- GFP2-Orp1 (Mito-roGFP2-Orp1), doxycycline (doxy), weeks of age (wo), Tafazzin -Knockdown ( Taz -KD), Wildtype (WT), Dithiothreitol (DTT), glucose (Glu, G), catalase (Cat), peroxiredoxin 3 (Prx3), glutathionperoxidase 4 (GPX4), area under the curve (AUC).

Article Snippet: Doxycycline (doxy) in a concentration of 625 mg of doxy/kg was added to the standard rodent chow (A153D70623, Ssniff, Germany) leading to induction of short hairpin RNA (shRNA)-mediated knockdown of Taz , as described previously ( ).

Techniques: shRNA, In Vivo, Isolation, Staining, Control, Imaging, Ex Vivo, Incubation, Western Blot, Knockdown

Peak plasma concentration of Lopinavir/Ritonavir (LOPIRITO), Azithromycin (AZI), Clarithromycin (CLA), Doxycycline (DOXY), Hydroxychloroquine (HCQ), and Favipiravir (FAVI) after a single oral administration of the drug.

Journal: PLoS ONE

Article Title: An in vitro study of dual drug combinations of anti-viral agents, antibiotics, and/or hydroxychloroquine against the SARS-CoV-2 virus isolated from hospitalized patients in Surabaya, Indonesia

doi: 10.1371/journal.pone.0252302

Figure Lengend Snippet: Peak plasma concentration of Lopinavir/Ritonavir (LOPIRITO), Azithromycin (AZI), Clarithromycin (CLA), Doxycycline (DOXY), Hydroxychloroquine (HCQ), and Favipiravir (FAVI) after a single oral administration of the drug.

Article Snippet: Lopinavir-Ritonavir (LOPIRITO) was produced by Abbott Laboratories (Aluvia®, Chicago, USA); Favipiravir (FAVI) by Toyama Chemical (Fujifilm Group) (Avigan®, Japan); Azithromycin (AZI) tablets by Gentec Pharmaceutical Group (Spain); Clarithromycin (CLA) by Ind Swift Laboratories Limited (India); Doxycycline (DOXY) by Genero Pharmaceuticals (Doxicor®, Indonesia); Hydroxychloroquine (HCQ) by Imedco Djaja (Hyloquin®, Indonesia); and dimethyl sulfoxide by Sigma Aldrich (Singapore).

Techniques: Concentration Assay

The cytotoxicities of Lopinavir-Ritonavir (LOPIRITO) and Doxycycline (DOXY) as a single drug (left) and dual drug combination in constant and non-constant ratios (right) analysed by using CompuSyn Software (n = 3). At non-constant ratios of LOPIRITO 8 μg/mL + DOXY, LOPIRITO was added at a concentration of 8 μg/mL to each increased levels of DOXY i.e. 0.2, 2, 10, 100, and 400 μg/mL. On the other hand, DOXY was then added at a concentration of 2 μg/mL to each increased levels of LOPIRITO i.e. 0.2, 2, 10, 100, and 400 μg/mL to produce LOPIRITO + DOXY 2 μg/mL.

Journal: PLoS ONE

Article Title: An in vitro study of dual drug combinations of anti-viral agents, antibiotics, and/or hydroxychloroquine against the SARS-CoV-2 virus isolated from hospitalized patients in Surabaya, Indonesia

doi: 10.1371/journal.pone.0252302

Figure Lengend Snippet: The cytotoxicities of Lopinavir-Ritonavir (LOPIRITO) and Doxycycline (DOXY) as a single drug (left) and dual drug combination in constant and non-constant ratios (right) analysed by using CompuSyn Software (n = 3). At non-constant ratios of LOPIRITO 8 μg/mL + DOXY, LOPIRITO was added at a concentration of 8 μg/mL to each increased levels of DOXY i.e. 0.2, 2, 10, 100, and 400 μg/mL. On the other hand, DOXY was then added at a concentration of 2 μg/mL to each increased levels of LOPIRITO i.e. 0.2, 2, 10, 100, and 400 μg/mL to produce LOPIRITO + DOXY 2 μg/mL.

Article Snippet: Lopinavir-Ritonavir (LOPIRITO) was produced by Abbott Laboratories (Aluvia®, Chicago, USA); Favipiravir (FAVI) by Toyama Chemical (Fujifilm Group) (Avigan®, Japan); Azithromycin (AZI) tablets by Gentec Pharmaceutical Group (Spain); Clarithromycin (CLA) by Ind Swift Laboratories Limited (India); Doxycycline (DOXY) by Genero Pharmaceuticals (Doxicor®, Indonesia); Hydroxychloroquine (HCQ) by Imedco Djaja (Hyloquin®, Indonesia); and dimethyl sulfoxide by Sigma Aldrich (Singapore).

Techniques: Software, Concentration Assay

The cytotoxicities of Hydroxychloroquine (HCQ) and Doxycycline (DOXY) as a single drug (left) and dual drug combination in constant and non-constant ratios (right) analysed by using CompuSyn Software (n = 3). At non-constant ratios of HCQ + DOXY 2 μg/mL, DOXY was added at a concentration of 2 μg/mL to each increased levels of HCQ i.e. 0.2, 2, 10, 100, and 400 μg/mL. On the other hand, HCQ was then added at a concentration of 6 μg/mL to each increased levels of DOXY i.e. 0.2, 2, 10, 100, and 400 μg/mL to produce HCQ 6 μg/mL + DOXY.

Journal: PLoS ONE

Article Title: An in vitro study of dual drug combinations of anti-viral agents, antibiotics, and/or hydroxychloroquine against the SARS-CoV-2 virus isolated from hospitalized patients in Surabaya, Indonesia

doi: 10.1371/journal.pone.0252302

Figure Lengend Snippet: The cytotoxicities of Hydroxychloroquine (HCQ) and Doxycycline (DOXY) as a single drug (left) and dual drug combination in constant and non-constant ratios (right) analysed by using CompuSyn Software (n = 3). At non-constant ratios of HCQ + DOXY 2 μg/mL, DOXY was added at a concentration of 2 μg/mL to each increased levels of HCQ i.e. 0.2, 2, 10, 100, and 400 μg/mL. On the other hand, HCQ was then added at a concentration of 6 μg/mL to each increased levels of DOXY i.e. 0.2, 2, 10, 100, and 400 μg/mL to produce HCQ 6 μg/mL + DOXY.

Article Snippet: Lopinavir-Ritonavir (LOPIRITO) was produced by Abbott Laboratories (Aluvia®, Chicago, USA); Favipiravir (FAVI) by Toyama Chemical (Fujifilm Group) (Avigan®, Japan); Azithromycin (AZI) tablets by Gentec Pharmaceutical Group (Spain); Clarithromycin (CLA) by Ind Swift Laboratories Limited (India); Doxycycline (DOXY) by Genero Pharmaceuticals (Doxicor®, Indonesia); Hydroxychloroquine (HCQ) by Imedco Djaja (Hyloquin®, Indonesia); and dimethyl sulfoxide by Sigma Aldrich (Singapore).

Techniques: Software, Concentration Assay

The summary of antiviral activity (IC 50 ) of single and combination drugs against Vero cells infected with SARS-CoV-2 at an multiplicity of infection (MoI) value of 0.04.

Journal: PLoS ONE

Article Title: An in vitro study of dual drug combinations of anti-viral agents, antibiotics, and/or hydroxychloroquine against the SARS-CoV-2 virus isolated from hospitalized patients in Surabaya, Indonesia

doi: 10.1371/journal.pone.0252302

Figure Lengend Snippet: The summary of antiviral activity (IC 50 ) of single and combination drugs against Vero cells infected with SARS-CoV-2 at an multiplicity of infection (MoI) value of 0.04.

Article Snippet: Lopinavir-Ritonavir (LOPIRITO) was produced by Abbott Laboratories (Aluvia®, Chicago, USA); Favipiravir (FAVI) by Toyama Chemical (Fujifilm Group) (Avigan®, Japan); Azithromycin (AZI) tablets by Gentec Pharmaceutical Group (Spain); Clarithromycin (CLA) by Ind Swift Laboratories Limited (India); Doxycycline (DOXY) by Genero Pharmaceuticals (Doxicor®, Indonesia); Hydroxychloroquine (HCQ) by Imedco Djaja (Hyloquin®, Indonesia); and dimethyl sulfoxide by Sigma Aldrich (Singapore).

Techniques: Activity Assay, Infection

The efficacy (IC 50 ) evaluation of Lopinavir-Ritonavir (LOPIRITO), Favipiravir (FAVI), Azithromycin (AZI), Clarithromycin (CLA), Doxycycline (DOXY), and Hydroxychloroquine (HCQ) as a single drug in Vero cells infected with SARS-CoV-2 virus isolates for 24 hours (A), 48 hours (B), and 72 hours (C) analysed using CompuSyn Software at a multiplicity of infection (MoI) value of 0.04.

Journal: PLoS ONE

Article Title: An in vitro study of dual drug combinations of anti-viral agents, antibiotics, and/or hydroxychloroquine against the SARS-CoV-2 virus isolated from hospitalized patients in Surabaya, Indonesia

doi: 10.1371/journal.pone.0252302

Figure Lengend Snippet: The efficacy (IC 50 ) evaluation of Lopinavir-Ritonavir (LOPIRITO), Favipiravir (FAVI), Azithromycin (AZI), Clarithromycin (CLA), Doxycycline (DOXY), and Hydroxychloroquine (HCQ) as a single drug in Vero cells infected with SARS-CoV-2 virus isolates for 24 hours (A), 48 hours (B), and 72 hours (C) analysed using CompuSyn Software at a multiplicity of infection (MoI) value of 0.04.

Article Snippet: Lopinavir-Ritonavir (LOPIRITO) was produced by Abbott Laboratories (Aluvia®, Chicago, USA); Favipiravir (FAVI) by Toyama Chemical (Fujifilm Group) (Avigan®, Japan); Azithromycin (AZI) tablets by Gentec Pharmaceutical Group (Spain); Clarithromycin (CLA) by Ind Swift Laboratories Limited (India); Doxycycline (DOXY) by Genero Pharmaceuticals (Doxicor®, Indonesia); Hydroxychloroquine (HCQ) by Imedco Djaja (Hyloquin®, Indonesia); and dimethyl sulfoxide by Sigma Aldrich (Singapore).

Techniques: Infection, Software

The efficacy (IC 50 ) evaluation of dual combination of Lopinavir-Ritonavir (LOPIRITO), Azithromycin (AZI), Doxycycline (DOXY), Favipiravir (FAVI), Clarithromycin (CLA), and Hydroxychloroquine (HCQ) as a single drug in Vero cells infected with SARS-CoV-2 virus isolates for 24 hours (A), 48 hours (B), and 72 hours (C) analysed using CompuSyn Software at a multiplicity of infection (MoI) value of 0.04.

Journal: PLoS ONE

Article Title: An in vitro study of dual drug combinations of anti-viral agents, antibiotics, and/or hydroxychloroquine against the SARS-CoV-2 virus isolated from hospitalized patients in Surabaya, Indonesia

doi: 10.1371/journal.pone.0252302

Figure Lengend Snippet: The efficacy (IC 50 ) evaluation of dual combination of Lopinavir-Ritonavir (LOPIRITO), Azithromycin (AZI), Doxycycline (DOXY), Favipiravir (FAVI), Clarithromycin (CLA), and Hydroxychloroquine (HCQ) as a single drug in Vero cells infected with SARS-CoV-2 virus isolates for 24 hours (A), 48 hours (B), and 72 hours (C) analysed using CompuSyn Software at a multiplicity of infection (MoI) value of 0.04.

Article Snippet: Lopinavir-Ritonavir (LOPIRITO) was produced by Abbott Laboratories (Aluvia®, Chicago, USA); Favipiravir (FAVI) by Toyama Chemical (Fujifilm Group) (Avigan®, Japan); Azithromycin (AZI) tablets by Gentec Pharmaceutical Group (Spain); Clarithromycin (CLA) by Ind Swift Laboratories Limited (India); Doxycycline (DOXY) by Genero Pharmaceuticals (Doxicor®, Indonesia); Hydroxychloroquine (HCQ) by Imedco Djaja (Hyloquin®, Indonesia); and dimethyl sulfoxide by Sigma Aldrich (Singapore).

Techniques: Infection, Software

The concentration of single and combination drugs (at a mass ratio) that produced an undetected virus copy number in the in vitro antiviral study against Vero cells infected with SARS-CoV-2 at a multiplicity of infection (MoI) value of 0.04 at 24, 48, and/or 72 hours’ incubation.

Journal: PLoS ONE

Article Title: An in vitro study of dual drug combinations of anti-viral agents, antibiotics, and/or hydroxychloroquine against the SARS-CoV-2 virus isolated from hospitalized patients in Surabaya, Indonesia

doi: 10.1371/journal.pone.0252302

Figure Lengend Snippet: The concentration of single and combination drugs (at a mass ratio) that produced an undetected virus copy number in the in vitro antiviral study against Vero cells infected with SARS-CoV-2 at a multiplicity of infection (MoI) value of 0.04 at 24, 48, and/or 72 hours’ incubation.

Article Snippet: Lopinavir-Ritonavir (LOPIRITO) was produced by Abbott Laboratories (Aluvia®, Chicago, USA); Favipiravir (FAVI) by Toyama Chemical (Fujifilm Group) (Avigan®, Japan); Azithromycin (AZI) tablets by Gentec Pharmaceutical Group (Spain); Clarithromycin (CLA) by Ind Swift Laboratories Limited (India); Doxycycline (DOXY) by Genero Pharmaceuticals (Doxicor®, Indonesia); Hydroxychloroquine (HCQ) by Imedco Djaja (Hyloquin®, Indonesia); and dimethyl sulfoxide by Sigma Aldrich (Singapore).

Techniques: Concentration Assay, Produced, In Vitro, Infection, Incubation

The summary of the cytokine levels of Vero cells infected with SARS-CoV-2 isolates an multiplicity of infection (MoI) value of 0.04 at 24, 48, and 72 hours incubated with single and drug combinations. The data were in duplicates.

Journal: PLoS ONE

Article Title: An in vitro study of dual drug combinations of anti-viral agents, antibiotics, and/or hydroxychloroquine against the SARS-CoV-2 virus isolated from hospitalized patients in Surabaya, Indonesia

doi: 10.1371/journal.pone.0252302

Figure Lengend Snippet: The summary of the cytokine levels of Vero cells infected with SARS-CoV-2 isolates an multiplicity of infection (MoI) value of 0.04 at 24, 48, and 72 hours incubated with single and drug combinations. The data were in duplicates.

Article Snippet: Lopinavir-Ritonavir (LOPIRITO) was produced by Abbott Laboratories (Aluvia®, Chicago, USA); Favipiravir (FAVI) by Toyama Chemical (Fujifilm Group) (Avigan®, Japan); Azithromycin (AZI) tablets by Gentec Pharmaceutical Group (Spain); Clarithromycin (CLA) by Ind Swift Laboratories Limited (India); Doxycycline (DOXY) by Genero Pharmaceuticals (Doxicor®, Indonesia); Hydroxychloroquine (HCQ) by Imedco Djaja (Hyloquin®, Indonesia); and dimethyl sulfoxide by Sigma Aldrich (Singapore).

Techniques: Infection, Incubation

The docking scores of potential SARS-CoV-2 main protease inhibitor drug.

Journal: PLoS ONE

Article Title: An in vitro study of dual drug combinations of anti-viral agents, antibiotics, and/or hydroxychloroquine against the SARS-CoV-2 virus isolated from hospitalized patients in Surabaya, Indonesia

doi: 10.1371/journal.pone.0252302

Figure Lengend Snippet: The docking scores of potential SARS-CoV-2 main protease inhibitor drug.

Article Snippet: Lopinavir-Ritonavir (LOPIRITO) was produced by Abbott Laboratories (Aluvia®, Chicago, USA); Favipiravir (FAVI) by Toyama Chemical (Fujifilm Group) (Avigan®, Japan); Azithromycin (AZI) tablets by Gentec Pharmaceutical Group (Spain); Clarithromycin (CLA) by Ind Swift Laboratories Limited (India); Doxycycline (DOXY) by Genero Pharmaceuticals (Doxicor®, Indonesia); Hydroxychloroquine (HCQ) by Imedco Djaja (Hyloquin®, Indonesia); and dimethyl sulfoxide by Sigma Aldrich (Singapore).

Techniques: Protease Inhibitor, Molecular Weight